Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced some fresh clinical results from its work in treating non-active secondary progressive multiple sclerosis (MS) with intranasal foralumab.
The work has focused particularly on reducing the amount of fatigue experienced by MS sufferers. Davis emphasises that the fatigue experienced by MS patients is not the typical tiredness most people feel, but a debilitating condition that severely impacts their quality of life.
In Tiziana’s expanded access programme, four out of six patients showed a reduction in this fatigue – a ratio Davis describes as “exciting” considering the severe impact of fatigue on MS sufferers. The company’s recent PET scan results and ongoing Phase 2a trials aim to further understand the drug’s profile and help move it towards approval. Davis hinted that the next update from the company will focus on their Phase 2a trials.
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/tiziana-life-sciences-reveals-exciting-clinical-data-from-latest-ms-trial-433395498
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of Tiziana Life Sciences plc (TLSA) and does not buy, sell, or trade any shares of (TLSA). This article does not provide a professional analysis of a (TLSA) financial position. (TLSA) financial position and all other information regarding the featured Company should be verified directly with (TLSA). Please read our full disclaimer for more detailed information.